BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Form S-1 — May 20, 2026
Brainstorm Cell Therapeutics Inc. (BCLI) filed an S-1 registration statement to allow selling securityholders to resell up to 7,796,496 shares of common stock, including shares issuable upon exercise of pre-funded warrants and common stock purchase warrants. The company will not receive proceeds from these sales, except for the nominal exercise prices of the warrants, indicating this is a secondary offering driven by existing investors rather than capital raising for operations. The filing reveals significant financial distress, with the independent auditor expressing substantial doubt about the company’s ability to continue as a going concern.
Key figures
- Offering Price
- 0.0005 to 1.45
- Shares Offered
- 7796496
- Common Shares
- 1310528
- Last Reported Price
- 0.716
- Common Warrant Shares
- 4252634
- Warrant Exercise Price1
- 1
- Warrant Exercise Price2
- 1.45
- Pre Funded Exercise Price
- 0.0005
- Pre Funded Warrant Shares
- 2233334
Price after filing
Close on the filing date to close N calendar days later (from $0.72). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.